Citation

Schmidt JG, Schneider WN. Neurorehabil. Neural Repair 2000; 14(2): 155-158.

Affiliation

Department of Rehabilitation and Neurology, St. Mary's Hospital, Unity Health Systems, Rochester, NY 14611, USA.

Copyright

(Copyright © 2000, American Society of Neurorehabilitation, Publisher SAGE Publishing)

DOI

unavailable

PMID

15470827

Abstract

OBJECTIVE: To describe the clinical effects of amantadine and propranolol in an agitated pediatric patient with cognitive deficits, hyperactivity, and hypersexualism secondary to "shaken-baby syndrome." BACKGROUND: Patients with shaken-baby syndrome can present with cognitive and behavioral impairments. CASE: A 9-year-old girl presented with cognitive impairments secondary to shaken-baby syndrome at 3 weeks of age. She was receiving many medications, including dextroamphetamine, methylphenidate, and clonidine, that were not effective in improving her cognitive status or decreasing her hypersexuality. She was weaned from stimulants and clonidine and prescribed amantadine 100 mg bid with improvement of attention, concentration, and cognition, although hypersexuality remained. She was then started on propranolol 10 mg tid and a gradual increase to 40 mg tid with amelioration of hypersexuality and hyperactivity and no unwanted effects noted. Self-weaning of propranolol was associated with the return of hypersexuality. The combination of amantadine and propranolol led to improvement of cognition and behavior, especially intellectual functioning and appropriate socialization with peers, respectively. CONCLUSION: Cognitive deficits and hypersexuality with hyperactive features due to shaken-baby syndrome may respond to the drug regimen of amantadine and propranolol.

Language: en